Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Tonix Pharma ( (TNXP) ).
On October 22, 2025, Tonix Pharmaceuticals announced that the first patient was dosed in the FOCUS study at Massachusetts General Hospital, targeting adult patients with arginine-vasopressin deficiency (AVP-D). The study is a randomized, double-blind, placebo-controlled crossover pilot designed to evaluate the company’s intranasal potentiated oxytocin products, TNX-2900 and TNX-1900, on markers of anxiety, depression, and socioemotional functioning. This trial aims to generate preliminary data for future studies on oxytocin replacement therapy, potentially impacting the treatment landscape for AVP-D and improving patient quality of life.
The most recent analyst rating on (TNXP) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
Tonix Pharma’s overall score is driven by strong corporate events, particularly the FDA approval of Tonmya, which significantly boosts its market potential. However, challenges in profitability and valuation weigh down the score. Mixed technical indicators suggest cautious optimism.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals is a fully-integrated biotechnology company with marketed products and a pipeline of development candidates. The company’s development portfolio focuses on central nervous system disorders, immunology, immuno-oncology, rare diseases, and infectious diseases. Tonix has received FDA approval for Tonmya, a non-opioid analgesic for fibromyalgia, and markets treatments for acute migraine. Their rare disease portfolio includes TNX-2900 for Prader-Willi syndrome, and they are developing vaccines and antibodies for diseases like mpox, smallpox, and Lyme Disease.
Average Trading Volume: 1,455,286
Technical Sentiment Signal: Strong Sell
Current Market Cap: $173.9M
For a thorough assessment of TNXP stock, go to TipRanks’ Stock Analysis page.